Rayner RayOne EMV IOL Receives FDA Approval
Rayner has received U.S. Food and Drug Administration approval for it's non-diffractive RayOne EMV IOL, which the company calls, "An effective solution for patients when diffractive IOLs may be cost-prohibitive or if there are concerns about dysphotopsia." The company adds that the lens was developed in collaboration with Australian surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons.
Dr. Mariano Royo, director of ophthalmology at the Hospital San Rafael in Madrid and director of the Ophthalmic Institute of Madrid, performed a study of 22 eyes of 11 patients implanted with RayOne EMV measured at six months postop. Dr. Royo reported that 100 percent of the patients achieved spectacle independence in the distance and intermediate range. The average reading add at 33 cm was reported to be +1.5 D, and one in three patients had functional near vision without the need for spectacles.1
Patient outcomes for RayOne EMV can be tracked using RayPRO, a free contactless telehealth solution that collects three years’ worth of patient reported outcomes after cataract or refractive surgery. To request clinical results from Dr. Royo's study, more information on RayOne EMV or an evaluation, contact: USMarketing@rayner.com. You can also visit the company website at https://rayner.com/us/.
1. Data on file. Rayner.
Lineage Presents More Data on OpRegen for Dry AMD with GA
Lineage Cell Therapeutics announced new interim results from its ongoing, 24-patient Phase I/IIa clinical study of its lead product candidate, OpRegen, an investigational cell therapy administering allogeneic retinal pigment epithelium cells to the subretinal space for the treatment of dry age-related macular degeneration with geographic atrophy. Overall, 75 percent of cohort 4 patients’ treated eyes were at or above baseline visual acuity at their last assessment, based on per protocol-scheduled visits ranging from three months to >2 years post-transplant. Improvements in best-corrected visual acuity reached up to +19 letters on an EDTRS chart. Learn more.
ProQR Announces Results from QR-421a Trial
ProQR Therapeutics announced results from a planned analysis of its Phase I/II Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa due to USH2A exon 13 mutations. In the trial, the company says that QR-421a demonstrated benefits on multiple measures of vision, including visual acuity, visual fields and optical coherence tomography retinal imaging after a single dose. QR-421a was observed to be well-tolerated with no serious adverse events, the company says. Read more.
SemaThera Enters Into Research Collaboration & Exclusive License Agreement with Roche
SemaThera announced the signing of a multi-year research collaboration and licensing agreement with Roche. The partnership will focus on developing SemaThera’s new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases. SemaThera holds exclusive rights to various technologies in which Semaphorin 3A is involved in neo-angiogenesis, senescence and neuronal regeneration.
New Website Supports AMD Patients
The American Macular Degeneration Foundation, BrightFocus Foundation, MD Support, Prevent Blindness and The SupportSight Foundation launched AMD Central, an online resource that “provides information and tools from leading advocacy organizations to support age-related macular degeneration patients and the caregiver community.” Learn more.
Complimentary CME Education Videos
Prevent Blindness Names April as Women’s Eye Health and Safety Month
Prevent Blindness Named April as Women’s Eye Health and Safety Month to raise awareness on the fact that women are at higher risk for most eye diseases, and provide free information on topics ranging from possible vision changes during pregnancy to the safe use of eye cosmetics. Read more.